CAS 9025-35-8|α-galactosidase
| Common Name | α-galactosidase | ||
|---|---|---|---|
| CAS Number | 9025-35-8 | Molecular Weight | 192.602 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 324.4±22.0 °C at 760 mmHg |
| Molecular Formula | C9H5ClN2O | Melting Point | / |
| MSDS | / | Flash Point | 150.0±22.3 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | alpha-Galactosidase |
|---|---|
| Synonym | More Synonyms |
α-galactosidase BiologicalActivity
| Description | α-Galactosidase (EC 3.2.1.22), that is, α-galactosidase, is a glycoside hydrolase that widely exists in animals, plants and microorganisms, and is often used in biochemical research. α-Galactosidase catalyzes the hydrolysis of α-1,6-linked terminal galactose residues, including galactooligosaccharides, galactomannans, and galactolipids. Catalyzes many catabolic processes including cleavage of glycoproteins, glycolipids and polysaccharides[1]. |
|---|---|
| Related Catalog | Research Areas >>Others |
| References | [1]. Sonu Bhatia, et al. Microbial production and biotechnological applications of α-galactosidase. Int J Biol Macromol. 2020 May 1;150:1294-1313. |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 324.4±22.0 °C at 760 mmHg |
| Molecular Formula | C9H5ClN2O |
| Molecular Weight | 192.602 |
| Flash Point | 150.0±22.3 °C |
| Exact Mass | 192.009033 |
| LogP | 2.12 |
| Appearance of Characters | buffered aqueous solution |
| Vapour Pressure | 0.0±0.7 mmHg at 25°C |
| Index of Refraction | 1.663 |
| Storage condition | 2-8°C |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Phrases | 36/37/38 |
| Safety Phrases | 36/37-26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
Articles56
More Articles| High throughput screening for inhibitors of alpha-galactosidase. Curr. Chem. Genomics 4 , 67-73, (2011) Fabry disease is a rare X-linked lysosomal storage disorder caused by a deficiency in α-galactosidase A (GLA), which catalyzes the hydrolysis of terminal α-galactosyl groups from glycosphingolipids, s... | |
| Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A. Am. J. Physiol. Gastrointest. Liver Physiol. 306(2) , G140-6, (2014) A defect in the gene for the lysosomal enzyme α-galactosidase A (Gla) results in globotriaosylceramide (Gb3) accumulation in Fabry disease and leads to premature death from cardiac and cerebrovascular... | |
| Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE 7(10) , e47805, (2012) Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotr... |
Synonyms
| Agalsidase |
| E.C. 3.2.1.22 |
| alpha-Galactoside galactohydrolase |
| Melibiase |
| 2-Quinoxalinecarbonyl chloride |
| quinoxaline-2-carbonyl chloride |
| alpha-D-Galactosidase |
| alpha-GAL 600L |
| alpha-D-Galactopyranosidase |
| Alpha-Gal 1000 |
| Validase AGS |
| alpha-D-Galactoside galactohydrolase |
| Alpha Gal 500 |
| alpha-Galactosidase A |
| Sumizyme AGS |
